Synthesis and biological evaluation of atropisomeric tetrahydroisoquinolines overcoming docetaxel resistance in triple-negative human breast cancer cells

被引:0
|
作者
Song, Jayoung [1 ]
Kim, Ahreum [2 ]
Hong, Intaek [2 ]
Kim, Sangji [2 ]
Byun, Woong Sub [1 ]
Lee, Hyun Soo [3 ]
Kim, Hyung Sik [2 ]
Lee, Sang Kook [1 ]
Kwon, Yongseok [2 ]
机构
[1] Seoul Natl Univ, Nat Prod Res Inst, Coll Pharm, Seoul 08826, South Korea
[2] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea
[3] Sogang Univ, Dept Chem, Seoul 04107, South Korea
基金
新加坡国家研究基金会;
关键词
Apoptosis; Atropisomerism; Docetaxel resistance; Isoquinolines; STAT3; Triple-negative breast cancer; DRUG; THERMOCHEMISTRY; TRANSFORMATION; CHEMISTRY; CHIRALITY;
D O I
10.1016/j.bioorg.2023.106573
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Herein, atropisomeric 8-aryltetrahydroisoquinolines have been synthesized and biologically evaluated. Based on our structure-activity relationship study, a highly bioactive racemic compound has been produced, and it exhibited high antiproliferative activities against various cancer cell lines, including docetaxel-resistant breast cancer cell lines. Each enantiomer can be synthesized in an enantioselective manner by employing the chiral phosphoric acid-catalyzed atroposelective Pictet-Spengler cyclization. An axially (R)-configured enantiomer showed a higher biological activity compared with the axially (S)-configured enantiomer. Further biological studies suggested that the (R)-enantiomer overcomes docetaxel resistance via the downregulation of signal transducer and activator of transcription 3 activation and consequently induces cellular apoptosis in docetaxel-resistant triple-negative breast cancer cell lines.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Design, synthesis and biological evaluation of new SIRT3 activators for the treatment of triple-negative breast cancer
    Huang, Guichan
    Wang, Hailing
    Zhao, Xi
    Wang, Chen
    Zhang, Jin
    Yao, Dahong
    Li, Chenyang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 118
  • [22] Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
    Caiazza, Francesco
    Murray, Alyson
    Madden, Stephen F.
    Synnott, Naoise C.
    Ryan, Elizabeth J.
    O'Donovan, Norma
    Crown, John
    Duffy, Michael J.
    ENDOCRINE-RELATED CANCER, 2016, 23 (04) : 323 - 334
  • [23] Synthesis of New Chromene Derivatives Targeting Triple-Negative Breast Cancer Cells
    Alneyadi, Aysha
    Nizami, Zohra Nausheen
    Aburawi, Hanan E. E.
    Hisaindee, Soleiman
    Nawaz, Muhammad
    Attoub, Samir
    Ramadan, Gaber
    Benhalilou, Nehla
    Al Azzani, Mazoun
    Elmahi, Yassine
    Almeqbali, Aysha
    Muhammad, Khalid
    Eid, Ali H. H.
    Vijayan, Ranjit
    Iratni, Rabah
    CANCERS, 2023, 15 (10)
  • [24] Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
    Park, So-Yeon
    Choi, Jang-Hyun
    Nam, Jeong-Seok
    CANCERS, 2019, 11 (07)
  • [25] Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer
    Patel, Ketan
    Chowdhury, Nusrat
    Doddapaneni, Ravi
    Boakye, Cedar H. A.
    Godugu, Chandraiah
    Singh, Mandip
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (12) : 4417 - 4426
  • [26] Synthesis and Optimization of the Docetaxel-Loaded and Durvalumab-Targeted Human Serum Albumin Nanoparticles, In Vitro Characterization on Triple-Negative Breast Cancer Cells
    Yurt, Fatma
    Ozel, Derya
    Tuncel, Ayca
    Gokbayrak, Ozde
    Aktas, Safiye
    ACS OMEGA, 2023, 8 (29): : 26287 - 26300
  • [27] MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
    Oudin, Madeleine J.
    Barbier, Lucie
    Schafer, Claudia
    Kosciuk, Tatsiana
    Miller, Miles A.
    Han, Sangyoon
    Jonas, Oliver
    Lauffenburger, Douglas A.
    Gertler, Frank B.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (01) : 143 - 155
  • [28] Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
    Zheng, Yiwen
    Li, Shujin
    Tang, Hongchao
    Meng, Xuli
    Zheng, Qinghui
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [29] Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells
    You, Kyu Sic
    Yi, Yong Weon
    Kwak, Sahng-June
    Seong, Yeon-Sun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (03) : 828 - 840
  • [30] Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
    Lamballe, Fabienne
    Ahmad, Fahmida
    Vinik, Yaron
    Castellanet, Olivier
    Daian, Fabrice
    Muller, Anna-Katharina
    Kohler, Ulrike A.
    Bailly, Anne-Laure
    Josselin, Emmanuelle
    Castellano, Remy
    Cayrou, Christelle
    Charafe-Jauffret, Emmanuelle
    Mills, Gordon B.
    Geli, Vincent
    Borg, Jean-Paul
    Lev, Sima
    Maina, Flavio
    ADVANCED SCIENCE, 2021, 8 (03)